The Role of Proteases in Processing of Tumour Associated Antigen (NY-ES0-1)
Article Sidebar
-
NY-ES0-1, Cancer Testis Antigen, MHC Molecules, Proteases, Antigen Processing
Abstract
The activation of T cell responses is reliant upon several steps: the uptake and processing/transforming of antigens into small peptides within specialist antigen presenting cells (APC); the binding of peptides to a class of major histocompatibility molecules (MHCs); the presentation of this complex on the surface of the APC; and the interaction of the T cell with the MHC-peptide complex. The melanoma-associated antigen (NY-ESO-1) is one of cancer testis antigens (CTAs). Because of the restricted expression of CTAs to germ cells, it has been suggested that the antigens belongs to this family could be a promising target for cancer vaccines and/or cancer immunotherapy. Therefore, their presentation to the T cells need to be elucidated for design a successful cancer vaccines. This study aims to highlight the processing of NY-ESO-1 antigen inside APC and the enzymes that are engaged in this process. The mechanisms of antigen processing of the immunogenic epitope from NY-ESO-1 antigen were studied using antigen presentation assays followed by ELISA and ELISpot, The results demonstrated that the treatment of the Dendritic cells (DCs) with the protease inhibitors affected the processing of the NY-ESO-1 protein. This indicates that the NY-ESO-1 protein requires proteolysis using proteases which are involved in the major processing (i.e., cysteine and aspartic proteases) for effective presentation to CD4 T cells. It also requires a low pH environment. In conclusion, the findings of the present study may provide further indications that, potentially, a NY-ESO1 antigen could be used in a cancer vaccine. This kind of study is at high importance for tumour immunity in terms of design tumour vaccines and modulation of tumour cells to function as antigen presenting cells and present their own antigens to the T cells.
Full text article
References
[1]-Janeway CA ., Travers P., Walport M and Shlomchik MJ . Immunobiology. 6thEd. Garland Science Publishing. 2005.
[2]-Kindt TJ., Goldsby RA and Osborne BA. Kuby Immunilogy .6thedition. 525-545. W.H.Freeman and Company. USA. 2007.
[3]-Law S.K.A.(1991). Antigen shedding and metastasis of tumour cells. Clin. exp. Immunol., 85, 1-2.
[4]-HöchstB and DiehlL. (2012). Antigen shedding into the circulation contributes to tumor immune escape. Oncoimmunology,1,1620–1622.
[5]-Boon T and van der Bruggen P (1996). Human Tumor Antigens Recognized by T Lymphocytes. J. Exp. Med., 183, 725-729.
[6]-Henderson RA and Finn OJ (1996). Human Tumor Antigens Are Ready to Fly. Adv. Immuno., 62, 217-256.
[7]-Parmiani G., De Filippo A., Novellino l and Castelli C (2007). Unique human tumor antigens : Immunobiology and use in clinical trials. J. Immunol , 178, 1975-1979.
[8]-Topalian SL., Gonzales M.., Parkhurst M., ELi Y., Southwood S., Sette A., Rosenberg SA and Robbins PE (1996). Melanoma-specific CD4 + T Cells Recognize Nonmutated HLA-DR-restricted Tyrosinase Epitopes. J. Exp. Med, 183, 1965-1971.
[9]-Loukinov D., Ghochikyan A., Mkrtichyan M ., Ichim TE., Lobanenkov VV., Cribbs DH and Agadjanyan MG (2006). AntitumorEfficacy of DNA Vaccination to the Epigenetically Acting Tumor Promoting Transcription Factor BORIS and CD80 Molecular Adjuvant. Journal of Cellular Biochemistry , 98, 1037–1043.
[10]-Gnjatic S., Nishikawa H., Jungbluth AA., Güre AO., Ritter G., Knuth A., ChenY-T. and Old LI. (2006). NY-ESO-1: Review of an immunogenic tumor antigen. Advances in Cancer Research, 95, 1-30.
[11]-ThomasR, Al-KhadairiG, RoelandsJ, HendrickxW, DermimeS, BedognettiD and DecockJ (2018) NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front. Immunol. 9:947.
[12]-Hunder NN ., Wallen H., Cao J., Hendricks DW., Reilly JZ., Rodmyre R., Jungbluth A., Gnjatic S., Thompson JA and Yee C (2008). Treatment of metastatic with autologous CD4+T cells against NY-ESO-1. NEJM, 358,2698-2703.
[13]-ChenW., Yewdell JW., Levine RL and Bennink JR (1999). Modification of cysteinresidues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. The Journal of Experimental Medicine,189, 1757-1764.
[14]-Nakagawa TY and Rudensky AY (1999). The role of lysosomal protteinase in MHC class II-mediated antigen processing and presentation. Immunol. Rev, 172, 121-129.
[15]-Bryant PW., Lennon-Dumenil A-M., Fiebiger E., Lagaudriere-Gesbert C and Ploegh H (2002). Proteolysis antigen presentation by MHC class II molecules. Advances in Immunology, 80, 70-114.
[16]-Musson JA., Hayward RD., Delvig AA., Hernan R.,Hormaeche CE., Koronakis V. and Robinson JH (2002). Processing of viable Salmonella typhimurium for presentation of a CD4 T cell epitope from Salmonella invasion protein (SipC). Eur. J. Immunol. , 32, 2664-2671.
[17]-Musson JA ., Walker N ., Flick-Smith H ., Williamson D and Robinson JH (2003). Differential processing of CD4 T-cells epitopes from the protective antigen of Bacillus anthracis. J. Bio. Chem ,278, 52425-5243.
[18]-Shim H-K., Musson JA., Harper HM., McNeill HV., Walker N., Flick-Smith H., von Delwig AA., Williamson ED and Robinson JH (2006). Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology, 119, 385–392.
[19]-Jensen PE (1993). Acidification and disulfide reduction can be sufficient to allow intact proteins to bind class II MHC. J.Immunol,150, 3347-3356.
[20]-Jensen PE (1995). Antigen unfolding and disulfide reduction in antigen presenting cells. Sem.Immunol,7, 347-353.
[21]-Griffin JP., Chu R and Harding CV (1997). Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J. Immunol , 158,1523-1532.
[22]-Lennon-Dumenil AM., Bakker AH., Wolf-Bryant P., Ploegh HL and Lagaudriere-Gesbert C (2002). A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr. Opin. Immunol, 14 , 15-21.
[23]-Honey K and Rudensky AY (2003). Lysosomal cysteine proteases regulate antigen presentation. Nature Rev. Immunol, 3, 472-482.
[24]-Bond JS and Butler PE (1987). Intracellular proteases. Ann. Rev. Biochem, 56 , 333-364.
[25]-Amoscato AA., Prenovitz DA and Lotze MT (1998). Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol, 160, 4023-4032.
[26]-Barretti AJ., Rawlings ND and Woessner JF. Handbook of proteolytic enzymes. Academic press, 1998.
[27]-Accapezzato D., Nisini R., Paroli M., Bruno G., BoninoF., Houghton M. and Barnaba V. (1998). Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis antigen. J. Immunol, 160 , 5262-5266.
[28]-Delvig AA and Robinson JH (1998a). Different endosomal proteolysis requirementfor antigen processing of two T-cell epitopes of the M5 protein from viable Streptococcus pyogenes. J Biol Chem, 273, 3291-3295.
[29]-Santambrogio L., Sato AK., Carven GJ., Belyanskaya SL., StromingerJL and Stern LJ (1999). Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad. Sci. USA, 96, 15056-15061.
[30]-Delvig AA., Ramachandra L., Harding CV and Robinson JH (2003). Localization of peptide/MHC class II complexes in macrophages following antigen processing of viable Streptococcus pyogenes. Eur. J. Immunol, 33 , 2353-2360.
[31]-Chai J-G (2012). Mechanisms of endogenous MHC class II presentation by tumour cells. Immunotherapy8(4): 777.
[32]-Matsuzaki J., Tsuji T., Luescher I OldLJ., ShrikantP., GnjaticS and OdunsiK(2013). Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumour recognition by NY-ESO-1 specific CD4+ T cells. Cancer Immunol Res2 (4): 341-50.
[33]-Pinet V., Vergelli M ., Martin R ., Bakke O and Long EO (1995). Antigen presentation mediated by recycling of surfaceHLA-DR molecules. Nature,375, 603–606.
[34]-Delvig AA and Robinson JH (1998b). Two T Cell Epitopes from the M5 protein of viable Streptococcus pyogenes Engage Different Pathways of Bacterial Antigen Processing in Mouse Macrophages. J Immunol, 160, 5267-5272.
[35]-von Delwig A., Bailey E., Gibbs DM. and Robinson JH. (2002). The route of bacterial uptake by macrophages influences the repertoire of epitopes presented to CD4 T cells. Eur. J. Immunol. , 32, 3714–3719.
[36]-Liu Y., Tian X., Leitner WW., et al., (2011). Polymeric structure and host toll-like receptor 4 dictate immunogenicity on NY-ESO-1 antigen in vivo. The Journal of Biological Chemistry, 286, 370077-370084.
[37]-Fonteneau JF., Brilot F., Munz C., and Gannage M.( 2016).The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer. The Journal of Immunology, 196: 64–71.
[38]-Jackson H., DimopoulosN., MifsudNA., et al., (2006). Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.J Immunol, 176, 5908-17.
[39]-BatchuRB., Moreno AM., SzmaniaSM., Bennett G., SpagnoliGC., PonnazhaganS., BarlogieB., Tricot Gand van Rhee F(2005). Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res., 65, 10041-9.
[40]-ZarourHM., MaillereB., BrusicV., et al., (2002). NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res.62, 213-8.
[41]-Gnjatic S., Atanackovic D., Jäger E., et al., (2003). Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses.PNAS, 100, 8862–8867.
[42]-Maraskovsky E., Slolander S., Drane DP., et al., (2004). NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vacine inducing both humoral and CD8+T-cell-mediated immunity and protection against NY-ESO-1+tumours. Clinical Cancer Research, 10, 2879-2890.
[43]-Jäger E., Karbach J., Gnjatic S., et al., (2006). Recombinant vaccinia_fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specificimmune responses in cancer patients. PNAS, 103 , 14453–14458.
[44]-Valmori D., Lévy F., Godefroy E., et al.,(2007a). Epitope clustering in regions.
[45]-undergoing efficient proteasomal processing defines immunodominantCTL regions of a tumor antigen. Clinical Immunology, 122, 163-172.
[46]-Valmori D., Souleimanian NE., Tosello V., et al., (2007b). Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. PNAS, 104, 8947–8952.
[47]-Odunsi K., Qian F., Matsuzaki J., et al., (2007). Vaccination with an NY-ESO-1 peptide of HLA class I/II specificity induces integrated humoral and T cell responses in ovarian cancer. PNAS, 104, 12837-12842.
[48]-Adams S., O’Neill DW., Nonaka D., et al., (2008). Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. The Journal of Immunology,181, 776–784.
[49]-Diefenbach CSM., Gnjatic S,. Sabbatini P., et al., (2008). Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clin Cancer Res, 14, 2740-48.
[50]-Bioley G., Guillaume P., LuescherI., YehA., Dupont B., BhardwajN., Mears G., Old LJ., ValmoriDand AyyoubM(2009). HLA Class I-Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumour Antigen Vaccine. Clin Cancer Res, 15, 299-306.The Journal of Experimental Medicine, 189, 1757-1764.
[51]-Gnjatic S., Altorki NK., NgTang D., Tu S-M., Kundra V., Ritter G., Old JI., Logothetis CJ. and Sharma P. (2009). NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Cancer Res, 15, 2130-39.
[52]-Ayyoub M., PignonP., Dojcinovic D., Raimbaud I., OldLJ., Luescher Iand Valmori D (2010). Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers. Clin Cancer Res, 16, 4607–15.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the University of Sebha where authors who have published their articles in the journal of the university of Sebha should how they can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
Privacy Statement The names and e-mail addresses entered on the Sabha University Journal site will be used for the aforementioned purposes only and for which they were used.